Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.72 |
| ▸ | GALR3 | O60755 | 1/20 | 0.72 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.72 |
| ▸ | GPR183 | P32249 | 1/20 | 0.72 |
| ▸ | RAB9A | P51151 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.72 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9235418 | 0.90 | MEN1 (0.72) | MEN1NPC1GALR3NR2F2GPR183 | |
| SCHEMBL3897719 | 0.89 | MEN1 (0.71) | MEN1NPC1GALR3NR2F2GPR183 | |
| SCHEMBL19766257 | 0.88 | MEN1 (0.59) | MEN1NPC1GALR3NR2F2GPR183 | |
| SCHEMBL9240901 | 0.87 | MEN1 (0.68) | MEN1NPC1GALR3NR2F2GPR183 | |
| SCHEMBL4958414 | 0.86 | MEN1 (0.74) | MEN1NPC1GALR3NR2F2GPR183 | |
| SCHEMBL10571776 | 0.86 | MEN1 (0.67) | MEN1NPC1GALR3NR2F2GPR183 | |
| SCHEMBL9237624 | 0.85 | MEN1 (0.76) | MEN1NPC1GALR3NR2F2GPR183 | |
| SCHEMBL9237017 | 0.85 | MEN1 (0.76) | MEN1NPC1GALR3NR2F2GPR183 | |
| SCHEMBL9775232 | 0.84 | MEN1 (0.74) | MEN1NPC1GALR3NR2F2GPR183 | |
| Pyridaben SCHEMBL27429 | 0.84 | MEN1 (1.00) | MEN1NPC1GALR3NR2F2GPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300878-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| EP-3385253-B1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING INC (US) | 2021-04-07 | — | — | EP | disclosed |
| US-10889550-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-20190127333-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2019-05-02 | — | — | US | disclosed |
| US-10125106-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-11-13 | — | — | US | disclosed |
| EP-3385253-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | Lantheus Medical Imaging, Inc. (US) | 2018-10-10 | — | — | EP | disclosed |
| US-20180009763-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-01-11 | — | — | US | disclosed |
| EP-1713512-B1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING INC (US) | 2018-01-10 | — | — | EP | disclosed |
| US-9718786-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20160130235-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2016-05-12 | — | — | US | disclosed |
| US-9161997-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. | 2015-10-20 | — | — | US | disclosed |
| US-20120276006-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-8226929-B2 | Administering to a patient a contrast agent (pyridimifen, fenazaquin) which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| EP-1713512-A4 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080112884-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-7344702-B2 | Contrast agents for myocardial perfusion imaging | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1713512-A2 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | Bristol-Myers Squibb Pharma Company (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005079391-A2 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050191238-A1 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009763-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | MEN1 154/4885NPC1 350/4885GALR3 549/4885 |
| US-20080112884-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | MEN1 154/4885NPC1 350/4885GALR3 549/4885 |
| US-20050191238-A1 | Contrast agents for myocardial perfusion imaging | TNNI3, TNNT2, FABP3 | MEN1 154/4885NPC1 350/4885GALR3 549/4885 |
| US-20190127333-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | MEN1 154/4885NPC1 350/4885GALR3 549/4885 |
| US-20160130235-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | MEN1 154/4885NPC1 350/4885GALR3 549/4885 |
| US-10125106-B2 | Contrast agents for myocardial perfusion imaging | TNNI3, TNNT2, FABP3 | MEN1 154/4885NPC1 350/4885GALR3 549/4885 |
| US-20210300878-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | MEN1 154/4885NPC1 350/4885GALR3 549/4885 |
| US-20120276006-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | MEN1 154/4885NPC1 350/4885GALR3 549/4885 |
| US-10889550-B2 | Contrast agents for myocardial perfusion imaging | TNNI3, TNNT2, FABP3 | MEN1 154/4885NPC1 350/4885GALR3 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.